Publications: Treatment Modalities

Posters:

ASCO 2026: Monitoring Blood Based Biomarkers As Early Predictors of Progression Free Survival in a Randomized Bria-ABC Phase 3 Trial for Advanced Metastatic Breast Cancer: An Ongoing Analysis
SABCS 2025: Prolonged survival following PD-L1/PD-1 immune checkpoint inhibitor therapy after leronlimab induced PD-L1 upregulation on cancer-associated macrophage-like cells and circulating tumor cells in patients with metastatic or locally advanced triple-negative breast cancer
ESMO 2025: Long Term Survival with Leronlimab Treatment in Patients with MetastaticTriple-Negative Breast Cancer (mTNBC)
SABCS 2024: PD-L1 Upregulation in Circulating Tumor Associated Cells Predicts for Clinical Outcomes in a Phase 1/2 Clinical Trial Using SV-BR-1-GM Vaccine with the Check Point Inhibitor Retifanlimab in Metastatic Breast Cancer Patients, an Interim Analysis
AACR 2022: Changes in Circulating Tumor Associated Cells Predicts Progression Free and Overall Survival in Metastatic TNBC Patients after Induction with the Anti-CCR5 Drug Leronlimab
SABCS 2022: Decreases in Circulating Tumor Associated Cells Predict PFS and OS in a Pooled Analysis of Phase I Clinical Trials Using SV-BR-1-GM Therapy with or without Immune Check-Point Inhibitors in Metastatic Breast Cancer Patient
Keystone Symposium Conference: SV-BR-1-GM, a breast cancer cell line with features of dendritic cells, induces tumor regression in HLA matched Stage IV breast cancer patients

Journals:

Clin Cancer Res 2025: Pembrolizumab in Combination with Binimetinib in Patients with Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer